Making HDAC6-targeted treatments work better for breast cancer
Official title: Investigating the Molecular Determinants Driving Response and Resistance to HDAC6 Targeted Therapy in Breast Cancer
Funded at Icahn School of Medicine at Mount Sinai · NIH-11284009 · Data updated 2026-11-12
This work looks at how blocking HDAC6 affects breast cancers and finds which patients are most likely to benefit.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 5, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $569,181 |
| NIH project number | 5R01CA274251-03 |
| Project ID | NIH-11284009 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with breast cancer—especially metastatic cases—whose tumors test positive on the HDAC6‑score biomarker.
✕Less likely to help
People whose tumors have a low HDAC6‑score or who have cancers other than breast cancer are unlikely to benefit from HDAC6-targeted approaches.
What this research studies
If you join, researchers will use tumor samples, lab models, and past patient data to learn why some breast cancers respond to drugs that block HDAC6 while others resist them. They will use a validated HDAC6‑score (available through a New York CLIA test) to match tumor biology with response and study how blocking HDAC6 causes cMyc to be marked for destruction by the cell's proteasome. The team will also examine samples and results from a prior treatment combining the HDAC6 inhibitor ricolinostat with nab‑paclitaxel to find molecular signs of benefit or resistance. The findings would be used to help match people to HDAC6-based therapies and to design better treatment combinations.
Why it matters
Potential benefit: If successful, this work could help identify who will benefit from HDAC6-targeted drugs and guide better combination treatments for breast cancer.
How similar studies have gone: Earlier clinical work combining the HDAC6 inhibitor ricolinostat with nab‑paclitaxel was well tolerated and showed clinical activity in metastatic breast cancer, supporting further study.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Silva, Jose M — Icahn School of Medicine at Mount Sinai
- Study coordinator: Silva, Jose M
Related research
Other NIH-funded projects on the same topics.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Overcoming Resistance to Targeted Therapy in Breast Cancer
Researchers are studying why some breast cancers stop responding to targeted therapies and what can be done to overcome this resistance.
-
PET scans to track glutamine use in triple-negative breast cancer
This project uses special PET scans with an amino-acid tracer to see how triple-negative breast cancers use glutamine so doctors can better match metabolism-targeted treatments to patients.
-
Improving Targeted Therapy for Triple Negative Breast Cancer
This project aims to develop a new way to deliver targeted medicines directly to triple-negative breast cancer tumors using special RNA molecules.
-
Using PET imaging to understand glutamine metabolism in triple-negative breast cancer
This study is looking at how a substance called glutamine affects triple-negative breast cancer to find better ways to treat it, using special imaging to see how much glutamine is in the cancer cells and helping doctors choose the best therapies for patients.
-
Understanding how HDAC6 affects breast cancer treatment responses
This study is looking at how a protein called HDAC6 affects breast cancer treatment, hoping to find out which patients might do better with new therapies that target this protein, so they can get more effective care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.